Target
B7-H3
9 abstracts
Abstract
ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.Org: Musculoskeletal Tumor Center, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM.Org: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China, Fuzhou Tcelltech Biological Science and Technology Inc., Fuzhou, China, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, Yale Cancer Center, New Haven, CT,
Abstract
ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).Org: Hunan Provincial Oncology Hospital, Peking University Shougang hospital, The First Affiliated Hospital of Gannan Medical College, Yuebei People's Hospital,
Abstract
A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.Org: Division of Biostatistics and Bioinformatics,
Abstract
A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors.Org: Excelmab Inc., Guangzhou, China,
Abstract
STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.Org: Seattle Children’s Research Institute, Seattle Childrens Research Institute,
Abstract
Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.Org: Caris Life Sciences, Irving, TX, Barbara Ann Karmanos Cancer Institute, St. John's Cancer Institute, Santa Monica, CA, Brown University - Lifespan Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Clinical Research Institute at Rambam, Rambam Medical Center,
Abstract
ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.Org: Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,